Dapivirine vs Emtricitabine/tenofovir disoproxil fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Dapivirine · Dapivirine Vaginal Ring
Marketed by Population Council and partners
NCT01617096 · Phase 3 · completed
This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.
Reported efficacy
Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)
Result source: NCT01617096
Emtricitabine/tenofovir disoproxil fumarate · Truvada
Marketed by Gilead Sciences
NCT00323544 · Phase 3 · completed
This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07584122 (registry estimate)
Reported efficacy
The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)
Result source: NCT00323544
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Dapivirine | Emtricitabine/tenofovir disoproxil fumarate |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06250504 | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757805 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06250504 | —Not posted · NCT00323544 |
| CD4 count, change (week 48) | —Trial running · NCT06250504 | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578012 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Emtricitabine/tenofovir disoproxil fumarate
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
5 other results
- 85.2% vs 87.4% NCT01108510
- 73.1% vs 66% NCT02275780
- 72.1% vs 74.1% NCT01108510
- 77.9% vs 79.3% NCT01108510
- 71.6% vs 79.7% NCT01108510
HIV-1 RNA 50 copies/mL or more (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Emtricitabine/tenofovir disoproxil fumarate
- —Not posted · NCT00323544
CD4 count, change (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Emtricitabine/tenofovir disoproxil fumarate
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
12 other results
- 192.7 vs 185.6 NCT02275780
- 310 vs 332 NCT01108510
- 277 vs 287 NCT01108510
- 291 vs 256 NCT00089505
- 223 vs 256 NCT00089505
- 213 vs 219 NCT01108510
- 172 vs 172 NCT00089505
- 350 vs 343 NCT01108510
- 191 vs 172 NCT00089505
- 158 vs 146 NCT01380080
- 96 vs 102 NCT01380080
- 8 vs 34 NCT00724711
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dapivirine: 4 of 4 rows · Emtricitabine/tenofovir disoproxil fumarate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapivirine | Emtricitabine/tenofovir disoproxil fumarate |
|---|---|---|
| Dropout rate | 11.3%25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results9.9%25 mg NCT02862171 · Phase 3 3.6%25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence — NCT03593655 · Phase 2 · registry result, not featured evidence 5.5% NCT02028338 · Phase 2 · registry result, not featured evidence 2.8% NCT02010593 · Phase 2 · registry result, not featured evidence 20.9%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 23.3%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence 10.5% NCT03239483 · Phase 1 · registry result, not featured evidence 31% NCT01539226 · Phase na · registry result, not featured evidence | 24.7%a NCT00458393 · Phase 3 show 15 more results16%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 24%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination 0%200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 24.2%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 79.9% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 25% NCT01195467 · Phase 3 · registry result, not featured evidence 19.5% NCT00625404 · Phase 3 · registry result, not featured evidence 25.5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 8.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results—25 mg NCT02862171 · Phase 3 —25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence — NCT03593655 · Phase 2 · registry result, not featured evidence — NCT02028338 · Phase 2 · registry result, not featured evidence — NCT02010593 · Phase 2 · registry result, not featured evidence 4.7%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence — NCT03239483 · Phase 1 · registry result, not featured evidence 0% NCT01539226 · Phase na · registry result, not featured evidence | —a NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 8%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence — NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 1.6%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 7.4% NCT01108510 · Phase 3 · registry result, not featured evidence · combination — NCT01195467 · Phase 3 · registry result, not featured evidence — NCT00625404 · Phase 3 · registry result, not featured evidence 5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence —NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence —NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 8.8%25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results2.1%25 mg NCT02862171 · Phase 3 1.4%25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence 0% NCT03593655 · Phase 2 · registry result, not featured evidence 2.7% NCT02028338 · Phase 2 · registry result, not featured evidence 1.4% NCT02010593 · Phase 2 · registry result, not featured evidence 2.3%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0% NCT03239483 · Phase 1 · registry result, not featured evidence 3.1% NCT01539226 · Phase na · registry result, not featured evidence | 7.5%a NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 0%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence 7.7% NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence 0%Truvada NCT00960622 · Phase 4 · registry result, not featured evidence 9.7% NCT00323492 · Phase 4 · registry result, not featured evidence 11.7%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 18.6% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 10% NCT01195467 · Phase 3 · registry result, not featured evidence 3.2% NCT00625404 · Phase 3 · registry result, not featured evidence 20.3%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 10.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg DVR inserted once every 4 weeksa metrorrhagia 55.1% (placebo 55.6%) genitourinary chlamydia infection 20.5% (placebo 20.8%) menorrhagia 19.7% (placebo 18.4%) NCT01617096 · Phase 3 · monotherapy show 9 more results25 mg vaginal matrix ring genitourinary chlamydia infection 8.4% vaginal discharge 8% vulvovaginitis trichomonal 5.9% NCT02858037 · Phase 3 · registry result, not featured evidence any event in soc 58.5% any event in soc 32.4% creatinine renal clearance decreased 30.3% NCT03593655 · Phase 2 · registry result, not featured evidence metrorrhagia 20.5% (placebo 26.1%) vaginal discharge 15.1% (placebo 34.8%) bacterial vaginosis 12.3% (placebo 8.7%) NCT02028338 · Phase 2 · registry result, not featured evidence vaginal discharge 11.1% (placebo 12.5%) upper respiratory tract infection 8.3% (placebo 12.5%) vaginal odour 6.9% (placebo 0%) NCT02010593 · Phase 2 · registry result, not featured evidence vaginitis bacterial 16.3% (placebo 11.9%) vaginal candidiasis 9.3% (placebo 0%) abdominal pain lower 4.7% (placebo 0%) NCT00799058 · Phase 1/2 · registry result, not featured evidence vaginitis bacterial 34.9% (placebo 11.9%) vulvovaginal pruritus 9.3% (placebo 4.8%) headache 7% (placebo 7.1%) NCT00799058 · Phase 1/2 · registry result, not featured evidence diarrhoea 11.1% (placebo 22.2%) insomnia 11.1% (placebo 0%) anal pruritus 5.6% (placebo 0%) NCT03239483 · Phase 1 · registry result, not featured evidence gynaecological chlamydia infection 32.7% (placebo 32.7%) metrorrhagia 27% (placebo 29.6%) genital infection female 23% (placebo 19.3%) NCT01539226 · Phase na · registry result, not featured evidence | a pharyngitis 20.2% (placebo 22.9%) parasitic infection intestinal 18.8% (placebo 17.6%) alanine aminotransferase increased 12.3% (placebo 12.6%) NCT00458393 · Phase 3 show 13 more resultserectile dysfunction 4.8% gastroenteritis 4.8% headache 4.8% NCT02401230 · Phase 4 · registry result, not featured evidence · combination gastroenteritis 5.3% pulmonary embolism 5.3% anxiety 0% NCT02401230 · Phase 4 · registry result, not featured evidence neutrophil count decreased 38% blood albumin decreased 35.6% blood sodium decreased 34% NCT01380080 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 9% diarrhea 8.4% cough 5.2% NCT00724711 · Phase 4 · registry result, not featured evidence · combination diarrhoea 9.7% abdominal pain 4.2% bronchitis 4.2% NCT00323492 · Phase 4 · registry result, not featured evidence 100 mg diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · registry result, not featured evidence 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination diarrhoea 22.1% jaundice 22.1% ocular icterus 20.1% NCT01108510 · Phase 3 · registry result, not featured evidence · combination bilateral arm pain 2.5% cellulitis 2.5% diarrhoea 2.5% NCT01195467 · Phase 3 · registry result, not featured evidence blood phosphorus decreased 19.4% (placebo 18.3%) aspartate aminotransferase increased 13.1% (placebo 11.5%) headache 13.1% (placebo 14.3%) NCT00625404 · Phase 3 · registry result, not featured evidence 400 mg b.i.d. nasopharyngitis 26.7% headache 26% diarrhoea 25.6% NCT00369941 · Phase 3 · registry result, not featured evidence cough 23.1% neutrophil count decreased 23.1% rash 23.1% NCT00089505 · Phase 3 · registry result, not featured evidence neutrophil count decreased 27.3% rash 26.5% cough 24.1% NCT00089505 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapivirine
Emtricitabine/tenofovir disoproxil fumarate
show 1 more result
show 3 more results
show 3 more results
show 13 more results
show 1 more result
show 5 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Emtricitabine/tenofovir disoproxil fumarate's landscape